In Glaxosmithkline Biologicals S.A v. The Minister of Health, 2020 FC 397, which is the Federal Court’s first judicial review of a decision made under the Patent Act and Certificate of Supplementary Protection Regulations (the “Regulations”), the Minister of Health’s (the “Minister”) decision was found to be unreasonable and was ordered to be redetermined on the merits.
Glaxosmithkline Biologicals S.A. (“GSK”) applied to the Minister for a Certificate of Supplementary Protection (“CSP”) for its patent on the vaccine SHINGRIX® (the “Patent”). The Minister found the Patent ineligible for a CSP (the “Decision”). A CSP would have effectively provided an additional patent-like protection term for the Patent.
The Court reviewed the Decision in light of the Supreme Court of Canada’s recent decision in Vavilov. After finding that the appropriate standard of review was reasonableness, the Court held that the Decision was unreasonable for failing to apply a purposive interpretation of the entire statutory framework.
The Minister’s Decision Regarding CSP Eligibility
The Minister interpreted the relevant statutory framework as requiring a patent to include a claim covering only medicinal ingredients to be eligible for a CSP. The Patent claimed combinations of an antigen and an adjuvant. The Minister acknowledged that the adjuvant was biologically active and necessary for SHINGRIX®’s clinical efficacy. Despite that, the Minister found the Patent ineligible for a CSP, as the Minister recognized only the antigen as a medicinal ingredient.
The Judicial Review Decision
On review, the Court determined that the applicable standard of review was reasonableness. Relying on Vavilov, the Court held that, in order for the Decision to be found reasonable, the Minister must have read the statutory language under consideration in its entire context and in its grammatical and ordinary sense harmoniously with the legislative scheme.
Under the Patent Act and Regulations, a CSP eligible patent is one that contains a claim for a “medicinal ingredient” or a combination of medicinal ingredients. However, “medicinal ingredient” is not defined. In the absence of a definition for “medicinal ingredient”, the Minister was required to look to Canada’s CSP statutory regime and resolve any interpretive ambiguities in a manner consonant with the broad purpose of the legislation.
The Court found that the relevant statutory framework includes the Canada-European Union Comprehensive Economic Trade Agreement (“CETA”), and that CETA “clearly” contemplates the grant of supplemental protection to inventive vaccines, which “often require both an antigen and an adjuvant to be effective”. CETA defines the protected product as “the active ingredient or combination of active ingredients” in the approved drug or vaccine [emphasis added].
Nothing in the Patent Act or Regulations expressly supported the Minister’s position that an eligible claim is only one that protects a “medicinal ingredient” per se. Furthermore, the Minister’s treatment of adjuvants as non-medicinal ingredients for purposes of granting a CSP was inconsistent with the Minister’s treatment of adjuvants in other contexts.
Authors: Larissa Fulop and Jon Wall
Authors
Expertise
Insights
-
Patent, Trademark and Copyright Litigation
Ferrari Makes Advances in Rear-Wheel Steering
Given this weekend's cancellation of Formula 1's Emilia Romagna Grand Prix at Imola, otherwise known as the "Autodromo Enzo e Dino Ferrari", the Goodmans IP Team decided to review some recent patent… -
Intellectual Property
From Paleo to Table: Food Tech Start Up Secures Patents for Heme-Based Proteins
Paleo, a food tech startup, has reportedly secured patents for “precision fermentation heme technology.” Heme is the molecule that is credited with the taste and texture of meat, and, while it is… -
Intellectual Property
Cochlear Increases Volume in Dispute With US University Over Hearing Device Patents
Cochlear, an Australian Biotech Hearing Implant Maker, will fight the University of Pittsburgh’s patent infringement claim that elements of Cochlear’s Nuclear 6 and 7 implant products violated their… -
Intellectual Property
New Patent Application Suggests Valve Could Cut The Cord on Virtual Reality Consoles
Valve, a video game developer and digital distribution company, may be planning a standalone virtual reality (VR) headset, according to PC Gamer. VR fans were excited to learn that Valve… -
Intellectual Property
Allstate Patent Application Speeds Towards More Data Driven Insurance
Allstate has reportedly filed a patent application for technology that would allow a telematics-based driving assessment in real time. While Allstate has aimed this technology at insurers to allow… -
Intellectual Property
Clint Eastwood "Bags" $2.6 Million in CBD Endorsement Case
Clint Eastwood has reportedly succeeded in receiving a default judgment against a CBD retailer for using his name and likeness to promote its products. In the suit, the Hollywood star claimed…